Indian doctor Reddy's aims to launch a generic obesity treatment at a price 60% lower.

HYDARABAD, Feb 17 (Reuters) - Dr. Reddy's Laboratories co-chairman and managing director G.V. Prasad told Reuters on Tuesday that the Indian drugmaker is seeking to launch a generic version of Novo Nordisk's weight-loss drug Wegovi at a price about 60 percent lower than the original, a move that requires approval.

Last month, the company received approval from the Indian Drug Regulatory Authority to manufacture and sell the generic version of the popular diabetes drug Ozempic, and said it is awaiting approval for the generic version of the drug Wigovy as well.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.